The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

a new golden child could be emerging in the form of Beyfortus. During its first full year on the market, the respiratory syncytial virus (RSV) antibody easily broke the $1 billion sales threshold.

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...

Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more easily accessible across the country.

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Get Your Free Sample Market Report: What is behind the incessant drive of the beyfortus global market ? The increasing incidence of RSV cases continues to propel the market ahead. RSV is an ...

Two RSV vaccines were approved for use in Australia ... are picking up the tab for Sanofi-Aventis’ nirsevimab (sold as Beyfortus) for infants. This is widely used, and funded, in the US and ...

A vaccine designed to help protect babies from the respiratory syncytial virus (RSV) is now free during pregnancy. RSV is the ...

RSV is the most common cause of respiratory ... announced it would support national access to a monoclonal antibody, Beyfortus, which would provide protection to newborns and young children.